Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Neoplasms 2Neoplasm Metastasis 1Colorectal Neoplasms 1

Interventions

Bevacizumab 25Fluorouracil 23Leucovorin 22Cetuximab 22Oxaliplatin 19pembrolizumab 14Specimen Handling 11Irinotecan 10Nivolumab 8Magnetic Resonance Spectroscopy 8Biopsy 7atezolizumab 6fludarabine 5encorafenib 5Pemetrexed 5Panitumumab 5HMPL-013 5Gemcitabine 5Folfox protocol 5Cisplatin 5Carboplatin 5trifluridine tipiracil drug combination 4balstilimab 4Standard of Care 4Immunoglobulin G 4Disulfides 4Cyclophosphamide 4regorafenib 3fludarabine phosphate 3dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × Hepatectomy × 30 days × Clear all
NCT07612007 2026-06-01

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

Mayo Clinic

Phase 2 Not yet recruiting
80 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡